Bronchiolitis is one of the most common reasons for pediatric hospitalization in the United
States, incurring costs of $734 million each year. 1 Supportive care is the mainstay of
treatment, with numerous studies demonstrating the futility of adjunct therapies including
corticosteroids, b-agonists, epinephrine, and hypertonic saline. In this issue of Pediatrics,
Kalburgi and Halley 2 describe patterns of adoption of high-flow nasal cannula (HFNC)
therapy in general pediatric units in the United States and Canada, illustrating wide uptake …